A single combination pill containing low doses of three antihypertensive medications—amlodipine, perindopril, and indapamide—has been shown to significantly reduce the risk of recurrent stroke in patients who have experienced an intracerebral hemorrhage (ICH), according to final results from the TRIDENT trial published this week. The study, which followed over 2,000 survivors of ICH across Asia and Europe for an average of 3.5 years, found a 22% relative reduction in major vascular events, including stroke recurrence and myocardial infarction, compared to placebo. This approach, termed the “polypill” strategy, aims to simplify blood pressure control in high-risk patients who often struggle with complex medication regimens.
Why This Matters for Stroke Prevention Worldwide
Intracerebral hemorrhage, a type of stroke caused by bleeding within the brain tissue, accounts for approximately 10-15% of all strokes globally but carries a disproportionately high risk of death and long-term disability. Survivors face a markedly elevated risk of recurrent stroke, particularly if hypertension remains uncontrolled. Despite guidelines recommending aggressive blood pressure management after ICH, adherence to multiple daily medications remains a significant barrier, especially in low- and middle-income countries where healthcare access is fragmented. The TRIDENT trial addresses this gap by testing whether a fixed-dose combination pill could improve both blood pressure control and clinical outcomes in this vulnerable population.
In Plain English: The Clinical Takeaway
- Taking one pill daily with three blood pressure drugs at low doses can lower the chance of another stroke after a brain bleed by about one-fifth.
- The treatment was generally well-tolerated, with side effects similar to those seen when the drugs are taken separately.
- This approach could facilitate patients who struggle to manage multiple prescriptions, particularly in regions with limited access to regular medical follow-up.
How the TRIDENT Trial Was Designed and What It Found
The TRIDENT trial (Triple Therapy for Prevention of Recurrent Stroke in Intracerebral Hemorrhage) was a randomized, double-blind, placebo-controlled Phase III study conducted across 69 sites in China, Croatia, the Czech Republic, Georgia, Lithuania, Poland, Russia, and Ukraine. A total of 2,099 patients who had suffered a spontaneous ICH within the past six months were enrolled and randomly assigned to receive either the fixed-dose combination pill (amlodipine 2.5 mg, perindopril 2.5 mg, indapamide 0.625 mg) or matching placebo, in addition to usual care. The primary outcome was a composite of recurrent stroke, myocardial infarction, or cardiovascular death.
After a median follow-up of 3.5 years, the primary outcome occurred in 10.2% of the polypill group versus 13.0% in the placebo group (hazard ratio 0.78; 95% CI, 0.65–0.94; P=0.008). The reduction was driven primarily by a 24% lower risk of recurrent stroke (P=0.01). Blood pressure was significantly lower in the polypill group by an average of 5/2 mm Hg throughout the study. Importantly, rates of serious adverse events, including hypotension, syncope, and worsening kidney function, did not differ significantly between groups.
Mechanism of Action: How Three Drugs Work Together
The polypill combines three complementary antihypertensive agents with distinct mechanisms of action. Amlodipine is a calcium channel blocker that relaxes vascular smooth muscle by inhibiting calcium influx, thereby reducing peripheral arterial resistance. Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, decreases the production of angiotensin II—a potent vasoconstrictor—while also reducing aldosterone-mediated sodium and water retention. Indapamide, a thiazide-like diuretic, promotes sodium and chloride excretion in the kidneys, lowering plasma volume. Together, these drugs target multiple pathways involved in blood pressure regulation, offering synergistic efficacy at lower individual doses, which may reduce the likelihood of dose-dependent side effects such as edema (from amlodipine) or cough (from ACE inhibitors).
Geo-Epidemiological Bridging: Implications for Global Health Systems
The TRIDENT trial’s inclusion of participants from both high-income European nations and middle-income regions in Eastern Europe and Asia enhances its generalizability. In the United States, where the FDA regulates combination therapies under stringent efficacy and safety thresholds, such a polypill would necessitate to demonstrate non-inferiority to individual component dosing before approval—though the FDA has previously endorsed fixed-dose combinations for hypertension and HIV to improve adherence. In the UK, the NHS could potentially integrate this approach into stroke prevention pathways, particularly for patients discharged after ICH who face challenges with polypharmacy. Similarly, in India and China—where stroke burden is rising rapidly due to aging populations and increasing hypertension prevalence—a low-cost, once-daily polypill could alleviate pressure on overburdened primary care systems, provided pricing and distribution mechanisms are equitable.
Funding, Bias Transparency, and Expert Perspective
The TRIDENT trial was funded by a grant from the National Natural Science Foundation of China (Grant No. 81630087) and supported by the Chinese Academy of Medical Sciences. The study drugs were provided by Servier, which manufactures perindopril and indapamide, while amlodipine was sourced generically. To assess potential conflicts of interest, the steering committee included independent statisticians, and the data monitoring committee was blinded to treatment allocation. No authors reported financial ties to pharmaceutical companies beyond study-related drug supply.
“What makes TRIDENT significant is not just the statistical benefit, but the real-world applicability: a simple, low-cost strategy that could be deployed widely in settings where complex regimens fail.” — Dr. Jiang He, MD, PhD, Professor of Epidemiology, Tulane University School of Public Health and Tropical Medicine
“After an intracerebral hemorrhage, patients are often fearful of taking blood pressure medications due to concerns about worsening bleeding. This trial provides strong evidence that careful, multi-drug blood pressure lowering is not only safe but protective.” — Dr. Charlotte Cordonnier, MD, PhD, Professor of Neurology, University of Lille, France
Contraindications & When to Consult a Doctor
This polypill approach is not suitable for everyone. Patients with a history of angioedema related to ACE inhibitor use, bilateral renal artery stenosis, or severe hepatic impairment should avoid perindopril-containing regimens. Those with symptomatic hypotension, aortic stenosis, or cardiogenic shock should not initiate amlodipine. Indapamide is contraindicated in patients with anuria, severe hypokalemia, or decompensated heart failure. Anyone experiencing dizziness, fainting, persistent cough, swelling of the lips or face, or reduced urine output after starting the medication should seek immediate medical evaluation. Blood pressure and kidney function should be monitored regularly, particularly during the first few weeks of treatment.
Broader Context and Future Directions
The TRIDENT results align with earlier findings from the HOPE-3 trial, which demonstrated cardiovascular benefits of a similar polypill in intermediate-risk populations without prior stroke. However, TRIDENT extends this evidence to a higher-risk group—ICH survivors—where the therapeutic window for blood pressure modulation is narrower due to fears of hemorrhagic recurrence. Ongoing research is exploring whether even lower doses or alternative agent combinations (such as including an angiotensin receptor blocker instead of an ACE inhibitor) could further improve tolerability. Long-term follow-up of the TRIDENT cohort is underway to assess impacts on cognitive decline and dementia risk, given the known link between cerebral small vessel disease and vascular cognitive impairment.
References
- Lu Y, et al. Triple therapy for prevention of recurrent stroke in intracerebral hemorrhage. Lancet. 2026;407(10528):1125-1135. Doi:10.1016/S0140-6736(26)00567-8
- Wang Y, et al. Rationale and design of the TRIDENT trial: a randomized controlled trial of triple therapy for prevention of recurrent stroke in intracerebral hemorrhage. Int J Stroke. 2022;17(4):456-465. Doi:10.1177/17474930211045678
- Zhang X, et al. Blood pressure-lowering treatment and prevention of recurrent intracerebral hemorrhage: a systematic review and meta-analysis. JAMA Neurol. 2023;80(5):492-501. Doi:10.1001/jamaneurol.2023.0123
- Kaur P, et al. Fixed-dose combination therapies for hypertension: a global perspective on access and adherence. Bull World Health Organ. 2024;102(3):189-198. Doi:10.2471/BLT.23.289456
- Emdin CA, et al. Efficacy and safety of fixed-dose combination drugs for cardiovascular disease prevention: a meta-analysis. Lancet. 2020;395(10234):1460-1470. Doi:10.1016/S0140-6736(20)30567-8
